Anti-Oligomeric alpha-syn [10H (syn-10H)], Human IgG1, Fc Silent(tm), kappa

Absolute Antibody

Anti-Oligomeric alpha-syn [10H (syn-10H)], Human IgG1, Fc Silent(tm), kappa

9

The binding of this antibody to oligomeric forms of alpha-synuclein was confirmed using ELISA. This antibody is not capable of recognizing monomeric and fibrillar forms of alpha-synuclein. This antibody could recognize the late stage alpha-synuclein aggregates occurring during (10-22 day) time points. It was capable of binding aggregates with molecular masses of 42 and ~80 kDa corresponding to trimeric and hexameric forms in a western blot. The scFv version of this antibody inhibits aggregation of alpha-synuclein in vitro, blocks extracellular alpha-synuclein-induced toxicity in both undifferentiated and differentiated human neuroblastoma cell lines (SH-SY5Y), and specifically recognizes naturally occurring aggregates in Parkinsons disease but not in healthy human brain tissue (PMID: 19141614). A fusion protein comprising D5 scFv, cell pentrating peptide like penetratin were found to be effective in Lewy body disease. It specifically targeted alpha-syn oligomers and reduced the accumulation of alpha-syn and ameliorated functional deficits when delivered late in disease development (PMID: 27606342).

Functional Assay, Western Blot, ELISA

Research Use Only

Monoclonal

10H (syn-10H)

SNCA

synuclein alpha

NACP, PARK1, PARK4, PD1, alpha-synuclein, I+/--synuclein, non A-beta component of AD amyloid, synuclein alpha-140, synuclein, alpha (non A4 component of amyloid precursor)

Human

IgG1

Alpha-synuclein

This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques.

Human

-20°C,2°C to 8°C

41116161